Ascendis ready with clinical trial of another cancer drug
In January, Ascendis announced that its first potential cancer treatment was ready for clinical trials. The biotech company now seeks FDA approval to begin trials with a second cancer drug.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Ambitions grow in the Danish biotech company Ascendis Pharma. On Tuesday, the company announced that it has applied for FDA approval of clinical trials with yet another potential drug for cancer treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis ready for new hires after FDA approval
For subscribers
FDA approves Ascendis' weekly growth hormone
For subscribers
.jpg&w=384&q=75)
